NNVC stock forecast, quote, news & analysis
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections... Show more
NanoViricides (NNVC) Stock Analysis: Broad-Spectrum Antiviral NV-387 Moves Through Phase II Trials
Key Takeaways
- NanoViricides (NNVC) shares traded near $1.40 in late October 2026, roughly 7% higher than the approximately $1.30 closing level recorded about 30 days earlier.
- The company is advancing NV-387, its lead broad-spectrum antiviral candidate, through Phase II clinical trials for Mpox and Ebola in the Democratic Republic of the Congo (DRC).
- NanoViricides has no approved products and generates no revenue, and it continues to fund operations through equity offerings, warrants, and credit facilities.
- A Noble Financial analyst reiterated a Buy rating on the stock with a $6.00 price target, reflecting clinical-stage optimism rather than current fundamentals.
- Clinical milestones, financing activity, and outbreak-related headlines remain the dominant forces shaping investor sentiment in this micro-cap biotech.
- For additional details on the company's outlook, explore its Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how automated strategies are trading tickers like NNVC.
Current Market Snapshot
NanoViricides trades as a low-priced, highly volatile micro-cap on the NYSE American exchange. Over the trailing 30-day period, the stock moved from roughly $1.30 to around $1.40, a gain of approximately 7% that keeps it below the double-digit threshold. Trading activity in the shares has been driven almost entirely by clinical trial news flow rather than by earnings or revenue, given that the company is pre-revenue. Investor sentiment has swung between optimism around the start of Phase II trials in Africa and caution about the company's funding runway and dilution risk.
NanoViricides (NNVC) Business Overview and Competitive Position
NanoViricides, Inc. is a clinical-stage nanomedicine company headquartered in Shelton, Connecticut, focused on developing antiviral therapies built on its proprietary "nanoviricide" platform. The technology is designed to mimic the host-cell binding sites that viruses use, creating micelle-based drug candidates intended to attach to and dismantle enveloped virus particles before they can infect cells. The company licenses this technology from TheraCour Pharma, Inc.
Its lead candidate, NV-387, is a broad-spectrum antiviral being evaluated against Mpox, Ebola, respiratory viruses such as RSV and influenza, COVID, and measles. A second program, NV-HHV-1, targets herpesviruses including shingles. The company's value proposition rests on the breadth of its platform and its progress into human trials, but it remains an early-stage enterprise with no commercialized products and a history of operating losses.
Recent Developments Driving NNVC
The most significant recent catalyst was the start of Phase II clinical testing for NV-387. In September 2026, the company announced that a Phase II trial of NV-387 oral gummies as a treatment for Mpox had begun enrolling patients in the DRC, and it separately reported that a Phase II trial of NV-387 for Ebola had started enrollment and dosing. These milestones represent the first late-stage human evaluations of the drug's safety and effectiveness.
Additional supportive news followed through October, including updates that the Ebola trial was progressing and that the company would present at an investment conference. NanoViricides also filed its annual report for the fiscal year ended June 30, 2026. On the financing side, the company closed a roughly $2 million registered direct offering in May 2026 and has continued to rely on an at-the-market facility, warrants, and a $3 million line of credit from its founder. Management has disclosed that it does not currently have sufficient funding to pursue all of its planned objectives through mid-2027, a key consideration for investors.
Trending AI Robots
Tickeron's Trending AI Robots page is a curated hub for automated trading strategies. While Tickeron offers hundreds of AI trading bots that collectively trade thousands of tickers, only the top-performing and most relevant bots appear in this section, making it easier for users to filter through the broader universe. The bots vary widely in strategy, holding timeframe, and performance metrics, from short-term momentum approaches to longer-horizon trend models. For investors following volatile names such as NNVC, the page provides a way to see how algorithmic systems are positioning themselves across changing market conditions.
2026 Outlook and What Investors Should Watch
Looking ahead, the primary driver for NNVC will be the progress and interim data from its Phase II Mpox and Ebola trials in the DRC. Positive safety or efficacy signals could materially reshape the stock's valuation narrative, while setbacks or enrollment delays would likely pressure shares. Investors should also monitor the company's cash position and any new equity raises, given the disclosed going-concern considerations and the potential for dilution. Regulatory developments, including possible orphan drug designations, government stockpiling contracts, and non-dilutive grant funding, represent additional catalysts that could extend the runway and validate the platform. As with all clinical-stage biotechnology companies, results in animal models do not guarantee success in human trials, and the path to regulatory approval and commercialization remains lengthy and uncertain.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NNVC sees its Stochastic Oscillator ascending out of oversold territory
On November 10, 2026, the Stochastic Oscillator for NNVC moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 72 instances where the indicator left the oversold zone. In 59 of the 72 cases the stock moved higher in the following days. This puts the odds of a move higher at over 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
NNVC moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +7.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where NNVC advanced for three days, in 154 of 197 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NNVC as a result. In 90 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for NNVC turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 43 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NNVC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.881) is normal, around the industry mean (3.498). P/E Ratio (-3.220) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. NNVC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NNVC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of anti-viral therapeutics
Industry Biotechnology